This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ0H0NO_L.jpg
The global trial, which began in 2019, was conducted at over 50 sites.While no safety issues were identified with the vaccine regimen, the trial’s failure marks yet another setback in the search for an HIV vaccine.
Another HIV vaccine by J&J (NYSE:JNJ) also failed a mid-stage study in a population of young women in sub-Saharan Africa in 2021.
